As nicotine pouches continue to expand across global markets, policymakers and public health stakeholders are increasingly asking important questions about their safety profile, long-term health implications, and appropriate regulation. A
About GINN. The Global Institute for Novel Nicotine (GINN) is a membership-based association and the responsible voice of the novel nicotine sector. GINN represents small and medium-sized European manufacturers and
Nicotine should be regulated proportionately to its risks and in a manner that accelerates the decline of combustible smoking. It should not be governed through sweeping “endgame” narratives that treat
A Growing Divide in European Nicotine Policy The European Union is approaching a critical moment in nicotine regulation. As policymakers prepare for major revisions to the Tobacco Excise Directive (TED),
Understanding the Findings and Their Policy Implications As nicotine pouches continue to emerge in markets around the world, regulators face a familiar challenge: how should policymakers respond when new products
Why Emerging Nicotine Products Are Creating New Questions for Insurers The nicotine marketplace has changed dramatically over the past decade. Traditionally, insurance underwriting relied on a relatively simple distinction: applicants
A New Direction in European Nicotine Policy Over the past decade, Europe has been at the centre of some of the world’s most significant debates on tobacco harm reduction. Products
New Research Offers Insights into Consumer Interest and Smoking Status As nicotine pouches continue to gain attention from regulators, researchers, and public health stakeholders, an important question remains: who is
Examining the Scientific Case for Tobacco Harm Reduction As nicotine pouches become an increasingly prominent feature of nicotine policy discussions worldwide, debate often moves faster than the science itself. Regulators,
As nicotine products continue to evolve, regulators and researchers face a recurring challenge: how can the performance of new products be evaluated efficiently, accurately, and consistently without relying exclusively on
As governments consider how to regulate nicotine pouches, one model is becoming increasingly important: treating oral nicotine products not as general consumer goods, but as medicines, natural health products, poisons,
While the European Union does not currently have a dedicated framework for modern nicotine products, several jurisdictions have already developed regulatory approaches that provide useful reference points for policymakers. These